Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products

MLA

Liam Simms, et al. “Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products.” Frontiers in Toxicology, vol. 4, Feb. 2022. EBSCOhost, https://doi.org/10.3389/ftox.2022.747508.

APA

Liam Simms, Fan Yu, Jessica Palmer, Kathryn Rudd, Edgar Trelles Sticken, Roman Wieczorek, Fiona Chapman, Lukasz Czekala, Matthew Stevenson, & Grant O’Connell. (2022). Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products. Frontiers in Toxicology, 4. https://doi.org/10.3389/ftox.2022.747508

Chicago

Liam Simms, Fan Yu, Jessica Palmer, Kathryn Rudd, Edgar Trelles Sticken, Roman Wieczorek, Fiona Chapman, Lukasz Czekala, Matthew Stevenson, and Grant O’Connell. 2022. “Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products.” Frontiers in Toxicology 4 (February). doi:10.3389/ftox.2022.747508.